Key result
Enalapril therapy significantly reduced blood pressure (p<0.05) and improved plasma glucose control, reducing the M value from 19.6 to 10.1 (p<0.01) in hypertensive diabetics.
Why the study?
Does enalapril improve blood pressure, renal function, and glucose homeostasis in hypertensive patients with non-insulin-dependent diabetes mellitus?
Observational (n=9)
Does enalapril improve blood pressure, renal function, and glucose homeostasis in hypertensive patients with non-insulin-dependent diabetes mellitus?
Absolute Event Rate: 10.1% vs 19.6%
p-value: p=<0.01
Enalapril effectively reduces blood pressure while simultaneously improving renal blood flow and glucose homeostasis in patients with hypertension and type 2 diabetes.
Enalapril-associated glucose improvement in this case should not change practice; leaves open need for randomized confirmation in hypertensive type 2 diabetes.
The antihypertensive efficacy of enalapril and its effects on renal function and glucose homeostasis were investigated in 9 hypertensive patients with non-insulin-dependent diabetes mellitus. Enalapril therapy produced a significant fall in blood pressure (BP) (p less than 0.05) and a significant increase in renal blood flow (p less than 0.05) without a change in glomerular filtration rate. Furthermore, fasting plasma glucose was significantly reduced (p less than 0.01). Similarly, M value, as an index of plasma glucose control in diabetes, was significantly reduced from 19.6 to 10.1 (p less than 0.01). These findings suggested that the angiotensin-converting enzyme inhibitor enalapril was effective in reducing BP and improving renal function, and might improve glucose homeostasis in hypertensive diabetics.
No takes yet. Share an insight, caveat, or question.
Ueda et al. (2008) conducted an observational in Hypertension with non-insulin-dependent diabetes mellitus (n=9). Enalapril vs. Baseline was evaluated on M value (index of plasma glucose control) (p=<0.01). Enalapril therapy significantly reduced blood pressure (p<0.05) and improved plasma glucose control, reducing the M value from 19.6 to 10.1 (p<0.01) in hypertensive diabetics.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: